News
A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...
6don MSN
SRM Institute of Science and Technology has released the SRMJEEE 2025 phase two schedule. Online registration concludes on ...
Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...
Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...
The trial is expected to generate significant clinical data by late summer 2026. Allarity plans to pursue multiple advantaged ...
Karnataka's cabinet has approved the establishment of Quantum Research Park phase-2 at IISc Bengaluru, with a government ...
Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...
2d
Clinical Trials Arena on MSNAvenzo begins Phase I/II trial of CDK4 selective inhibitor for breast cancerUS-based Avenzo Therapeutics has commenced the open-label Phase I/II trial of its cyclin-dependent kinase 4 (CDK4) selective ...
Phase 2 data expected in 2H 2026 - - KPL-387 Phase 1 single ascending dose data support profile for monthly dosing - LONDON, ...
WATE Knoxville on MSN4d
KCDC breaks ground on Phase 2 of Western Heights projectThe Knoxville Community Development Corporation broke ground on Phase 2 of the Transforming Western initiative Wednesday.
Explore how the Air Force Safety Center's phase two of the Integrating Risk and Readiness campaign could empower airmen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results